According to UnivDatos, the growing prevalence of chronic diseases, increasing adoption of self-injection devices, rising demand for biologics and vaccines, advancements in syringe design and material safety, expanding healthcare infrastructure in Southeast Asia, government focus on immunization programs, and growing pharmaceutical manufacturing investments drive the Southeast Asia Prefilled Syringes market. As per the “Southeast Asia Prefilled Syringes Market” report, the market was valued at ~USD 307.45 million in 2024, growing at a CAGR of about 8.77% during the forecast period from 2025 to 2033 to reach USD million by 2033.

The Southeast Asia prefilled syringes market is going through a transition stage, which is driven by the modernization of healthcare, vaccination, and increasing demand for biologics. With pharmaceutical companies transitioning to non-conventional vials and ready-to-deliver systems, prefilled syringes are becoming the new standard in terms of safety, accuracy, and ease of use for patients. The region has been one of the most rapidly changing centers of injectable solutions, and countries such as Singapore, Vietnam, Thailand, and Indonesia are experiencing increased investments in manufacturing infrastructure, automation, and materials innovation.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/southeast-asia-prefilled-syringes-market?popup=report-enquiry

The Shift Toward Ready-to-Use Drug Delivery

The driving force of the market is the shift from traditional glass vials to prefilled syringes, which reduce contamination and dosage errors. The surge in demand has also been exacerbated by the emergence of self-administration, particularly in chronic illnesses and home care, as well as the need for user-friendly syringes that are tamper-proof. The filling lines, clean rooms, and technology used in packaging employed by manufacturers in Southeast Asia are also being automated, allowing companies to achieve international safety standards. Moreover, partnerships with international pharmaceutical companies enhance the transfer of technology and the development of local capacities.

On July 29, 2025, WuXi Biologics announced construction had begun for a new modular Drug Product (DP) facility, which will become part of the company’s CRDMO hub in Singapore. Under a strategic collaboration between WuXi Biologics and Pharmadule Morimatsu, 470 modular components are being fabricated at Morimatsu’s plant in Changshu City and will be transported to Singapore’s Tuas Biomedical Park for installation. Once complete, the building will be one of the world’s largest modular biologics DP facilities, comprising approximately 30,000 square meters of space.

The new facility will feature state-of-the-art manufacturing lines, centralized Quality Control (QC) labs supporting full release and stability testing, and Manufacturing Science and Technology (MSAT) labs, significantly enhancing the company’s end-to-end DP services capabilities. Equipped with three pre-filled syringe (PFS) production lines and two vial production lines for both liquid and lyophilized products.

The Plastic Revolution: Lightweight, Safe, and Scalable

The rising shift in preference towards plastic prefilled syringes instead of glass is a significant market trend. Plastic solutions are lighter, shatter-free, and more adaptable to the modern biologics, which are sensitive to leachable or breakages. This change in material not only enhances the safety and transportation efficiency, but it also suits the objectives of sustainability and cost-saving in large-scale production. Investments in cyclic olefin polymers (COP) and cyclic olefin copolymers (COC) are also assisting local manufacturers in increasing scale-up production with high barrier protection and sterility.

Rising Biologics and Vaccine Demand Driving Adoption

The increased demand for biologics and vaccines is one of the driving forces of the Southeast Asia Prefilled Syringes market. As the region is experiencing a rapid pace of biologic drug development and expanding immunization initiatives, drug companies are moving towards the use of prefilled syringes to ensure precise dosing and to minimize the chances of contamination. The COVID-19 crisis has increased the speed of vaccine infrastructure, and nations such as Singapore, Vietnam, and Indonesia have invested in an efficient drug delivery format. Prefilled syringes are convenient, sterile, and time-saving, and would be the best choice when using biologic formulations that need to be handled with care. This is an increasing biologics pipeline, which is driving manufacturers to automation and ready-to-use syringe solutions across the region.

Investments and Expansion of Strategies

The increasing demand is forcing local and multinational players to increase their investments in order to capitalize on it. The recent growth in Singapore and Malaysia has been directed at the implementation of smart manufacturing, robotics, and real-time quality control. The governments in the region are also offering incentives to increase local production capacity and foreign investment. Moreover, partnerships with biotech startups are accelerating the development of more advanced syringe designs, such as dual-chamber designs that are compatible with intricate formulations and lyophilized drugs.

On April 24, 2025, SCG Packaging Public Company Limited, also known as SCGP, announced that the company is implementing a strategy to enhance its capabilities in the growing healthcare supplies market, which continues to show strong growth potential. This involves entering the syringes and needles market. The company’s board of directors approved an investment project to expand syringes production capacity by 180 million units per year and needles production by 100 million units per year at VEM (Thailand) Company Limited (VEM-TH) in SCGP, Rayong Province, with a total investment of Baht 142.3 million (~USD 4.37 million). Production is expected to begin in January 2026.

Click here to view the Report Description & TOC https://univdatos.com/reports/southeast-asia-prefilled-syringes-market

Evolving Dynamics of the Southeast Asia Prefilled Syringes Market

The prefilled syringes market of Southeast Asia is at the crossroads of innovation, investment, and healthcare transformation. As biologic therapies continue to increase, vaccination campaigns, and with the transition to more plastic-based solutions, the market is expected to grow at an impressive pace in the next few years. The push toward localization of manufacturing and smart production in the region paves the way for continued growth and the reformation of the preparation, delivery, and trust of injectable drugs within the healthcare ecosystem.

Related Report:-

Polymer-Based Prefilled Syringe Market: Current Analysis and Forecast (2024-2032)

Pharmaceutical Sterile Fill-Finish Market: Current Analysis and Forecast (2023-2030)

Polymer-Based Prefilled Syringe Market: Current Analysis and Forecast (2024-2032)

MENA Syringes & Cannula Market: Current Analysis and Forecast (2024-2032)

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/